Overview

Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation

Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the pharmacodynamics (as expressed in intraocular pressure [IOP]) of two formulations of tafluprost 0.0015% eyedrops (preserved and unpreserved) in patients with open-angle glaucoma or ocular hypertension. The primary aim of this study is to show that IOP reduction between the two formulations is equivalent at the end of the 4 week treatment period.
Phase:
Phase 3
Details
Lead Sponsor:
Santen Oy
Treatments:
Ophthalmic Solutions
Tetrahydrozoline